In Parkinson’s disease (PD) there is a selective degeneration of neuromelanin-containing neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin accumulates with age, the latter being the main risk factor for PD. The contribution of neuromelanin to PD pathogenesis remains unknown because, unlike humans, common laboratory animals lack neuromelanin. Synthesis of peripheral melanins is mediated by tyrosinase, an enzyme also present at low levels in the brain. Here we report that overexpression of human tyrosinase in rat substantia nigra results in age-dependent production of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in elderly humans. In these animals, intracellular neuromelanin accumulation above a specific threshold is associated to an age-dependent PD phenotype, including hypokinesia, Lewy body-like formation and nigrostriatal neurodegeneration. Enhancing lysosomal proteostasis reduces intracellular neuromelanin and prevents neurodegeneration in tyrosinase-overexpressing animals. Our results suggest that intracellular neuromelanin levels may set the threshold for the initiation of PD.
Parkinson’s disease (PD) is a neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, for which no disease-modifying treatments exist. This lack of effective treatments is related to the advanced stage of neurodegeneration existing at the time of diagnosis. Thus, the identification of early stage biomarkers is crucial. Biomarker discovery is often guided by the underlying molecular mechanisms leading to the pathology. One of the central pathways deregulated during PD, supported both by genetic and functional studies, is the autophagy-lysosomal pathway. Hence, this review presents different studies on the expression and activity of autophagic and lysosomal proteins, and their functional consequences, performed in peripheral human biospecimens. Although most biomarkers are inconsistent between studies, some of them, namely HSC70 levels in sporadic PD patients, and cathepsin D levels and glucocerebrosidase activity in PD patients carrying GBA mutations, seem to be consistent. Hence, evidence exists that the impairment of the autophagy-lysosomal pathway underlying PD pathophysiology can be detected in peripheral biosamples and further tested as potential biomarkers. However, longitudinal, stratified, and standardized analyses are needed to confirm their clinical validity and utility.
Dopamine
is a key neurotransmitter in the pathophysiology of various
neurological disorders such as addiction or Parkinson’s disease.
Disturbances in its metabolism could lead to dopamine accumulation
in the cytoplasm and an increased production of o-quinones and their derivatives, which have neurotoxic potential
and act as precursors in neuromelanin synthesis. Thus, quantification
of the dopaminergic metabolism is essential for monitoring changes
that may contribute to disease development. Here, we developed and
validated an UPLC-MS/MS method to detect and quantify a panel of eight
dopaminergic metabolites, including the oxidation product aminochrome.
Our method was validated in differentiated SH-SY5Y cells and mouse
brain tissue and was then employed in brain samples from humans and
rats to ensure method reliability in different matrices. Finally,
to prove the biological relevance of our method, we determined metabolic
changes in an in vitro cellular model of dopamine
oxidation/neuromelanin production and in human postmortem samples
from Parkinson’s disease patients. The current study provides
a validated method to simultaneously monitor possible alterations
in dopamine degradation and o-quinone production
pathways that can be applied to in vitro and in vivo experimental models of neurological disorders and
human brain samples.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.